CraniUS Therapeutics Secures Second FDA 510(k) Clearance in Six Weeks and Earns U.S. Patent for NeuroPASS™ 3 Cranial Drug Delivery System

RegulatoryapprovedNeuroPASS 3NeuroPASS 2Positive

AI Analysis

Summary

CraniUS Therapeutics received FDA 510(k) clearance for its NeuroPASS 2 cranial drug delivery system, the second clearance in six weeks, and secured a U.S. patent for the NeuroPASS 3 integrated drug delivery architecture.

Outcome Details

FDA 510(k) clearance for CraniUS Plate configuration (NeuroPASS 2); U.S. patent issued for NeuroPASS 3 integrated drug delivery architecture

Importance:6/10

Sentiment:

0.80

FDA clearance510(k)Medical devicePatentDrug delivery systemCranial

Related Companies

$INBP

Read the original article

Published by PR Newswire Biotech on October 7, 2026 11:50 AM

Read Original